All In Biotech

Drug Trial Radar · NCT07490301

A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination With FOLFOX Compared to Standard of Care in Subjects With First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

900

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Jun 2031

Study completion Jun 2031

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably. The pancreas is a gland behind the stomach that produces a digestive fluid that is emptied into the intestines through tube shaped ducts. Pancreatic cancer often starts in these ducts. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan when given in combination with fluorouracil, folinic acid, and oxaliplatin (FOLFOX) to treat adult participants with pancreatic ductal cancer. Telisotuzumab adizutecan is an investigational drug being developed for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study will be divided into two phases, with the first phase (Phase 2) treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX. Participants will then be randomized into 3 groups called treatment arms. Two groups will receive telisotuzumab adizutecan with FOLFOX with different optimized doses. One group will receive standard of care (SOC) - fluorouracil, leucovorin, oxaliplatin, and irinotecan. In the second phase (Phase 3), participants will be randomized into 2 arms to receive either the optimal dose of telisotuzumab adizutecan (from the previous phase) with FOLFOLX, or SOC. Approximately 900 participants with PDAC will be enrolled in this study in approximately 200 sites worldwide. Phase 2 includes a dose escalation stage and a dose optimization stage. In the dose escalation stage, participants will receive escalating doses of Intravenous (IV) telisotuzumab adizutecan + FOLFOX. In the dose optimization stage, participants will receive 1 of 2 doses of IV telisotuzumab adizutecan with FOLFOX or SOC. At the start of Phase 3, participants will receive the optimal dose of IV telisotuzumab adizutecan with FOLFOX or SOC. The study will run for a duration of approximately 6 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma
  • PDAC

Interventions

  • Telisotuzumab adizutecanDrug

    Intravenous (IV) Infusion

  • FluorouracilDrug

    IV Infusion

  • Folinic acid/ LeucovorinaDrug

    IV Infusion

  • OxaliplatinDrug

    IV Infusion

  • IrinotecanDrug

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2 and Phase 3: Overall Response (OR) Assessed by Blinded Independent Central Review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: through study completion, approximately 6 years
  2. Phase 3: Overall Survival (OS)Time frame: through study completion, approximately 6 years

Locations

22 sites in 8 countries. Site status is shown where the registry gives one.

  • Smilow Cancer Center At Yale-New Haven /ID# 279780

    New Haven, Connecticut · Recruiting

  • University of Chicago Medical Center /ID# 279460

    Chicago, Illinois · Recruiting

  • City Of Hope - Chicago /ID# 279814

    Zion, Illinois · Recruiting

  • Cancer And Hematology Centers Of Western Michigan - Grand Rapids /ID# 279853

    Grand Rapids, Michigan · Recruiting

  • Washington University /ID# 279890

    St Louis, Missouri · Recruiting

  • UH Seidman Cancer Center /ID# 279602

    Cleveland, Ohio · Recruiting

  • University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 280038

    Philadelphia, Pennsylvania · Recruiting

  • Texas Oncology - Northeast Texas /ID# 280417

    Tyler, Texas · Recruiting

  • Virginia Cancer Specialists - Fairfax /ID# 280415

    Fairfax, Virginia · Recruiting

  • Austin Hospital /ID# 280283

    Melbourne, Victoria, Australia · Recruiting

  • Rambam Health Care Campus- Haifa /ID# 279409

    Haifa, Israel · Recruiting

  • Hadassah Medical Center-Hebrew University /ID# 279411

    Jerusalem, Israel · Recruiting

  • The Chaim Sheba Medical Center /ID# 279408

    Ramat Gan, Tel Aviv, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center /ID# 279414

    Tel Aviv, Tel Aviv, Israel · Recruiting

  • The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 280140

    Koto-ku, Tokyo, Japan · Recruiting

  • Unidade Local de Saude de Santa Maria /ID# 279884

    Lisbon, Portugal · Recruiting

  • Fundacao Champalimaud /ID# 279881

    Lisbon, Lisbon District, Portugal · Recruiting

  • Seoul National University Hospital /ID# 280191

    Seoul, Seoul Teugbyeolsi, South Korea · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 279735

    Kaohsiung City, Taiwan · Recruiting

  • China Medical University Hospital /ID# 279725

    Taichung, Taiwan · Recruiting

  • Taipei Veterans General Hospital /ID# 279726

    Taipei, Taiwan · Recruiting

  • Oxford University Hospital NHS Trust /ID# 279764

    Oxford, Oxfordshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.